Evidence map›Paper›PMID 41958926›Full record

ReviewFrontiers in pharmacology2026

Targeting cancer with delphinidin: from molecular insights to therapeutic implications.

Yuhong Xu, Bingqian Jin, Pingping Yin, Kaiwen Cheng, Qianqian Li, Haigang Ding

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuhong Xu *Department of Gynecology, Shaoxing People's Hospital (School of Medicine, Shaoxing University), Shaoxing, Zhejiang, China.
Bingqian Jin *The First Affiliated Hospital of Shaoxing University, Shaoxing, Zhejiang, China.
Pingping YinThe First Affiliated Hospital of Shaoxing University, Shaoxing, Zhejiang, China.
Kaiwen ChengDepartment of Medical Research Center, Shaoxing People's Hospital (School of Medicine, Shaoxing University), Shaoxing, Zhejiang, China.
Qianqian LiThe First Affiliated Hospital of Shaoxing University, Shaoxing, Zhejiang, China.
Haigang DingDepartment of Gynecology, Shaoxing People's Hospital (School of Medicine, Shaoxing University), Shaoxing, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Delphinidin is a natural anthocyanidin abundant in various fruits, vegetables, and flowers. It has garnered significant attention due to its potent antioxidant activity and extensive anticancer potential. This review systematically elaborates on its chemical structure, biosynthetic pathways, and therapeutic roles, with a focus on its molecular mechanisms, cancer-specific effects, and clinical challenges. Mechanistically, delphinidin exerts anticancer effects through multiple pathways, including anti-proliferative activity, promotion of apoptosis, regulation of autophagy, inhibition of migration and invasion, suppression of angiogenesis, modulation of the immune microenvironment, and chemosensitization. These multi-target actions contribute to its pronounced tumor-suppressive effects in a broad spectrum of cancers, including but not limited to breast, lung, liver, colorectal, prostate, and ovarian malignancies. Despite its promising preclinical efficacy, the clinical translation of delphinidin is primarily hindered by its low oral bioavailability and poor stability. Emerging strategies such as nano-delivery systems and structural modifications are being actively explored to overcome these limitations. In summary, as a multi-targeted, low-toxicity natural compound, delphinidin holds broad application prospects in cancer prevention, treatment, and combination therapy, provided that its pharmacological challenges can be successfully addressed.

Indexed as

cancerdelphinidinmechanismpharmacologyreview

Identifiers

PMID41958926
PMCPMC13056821

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.